About Event
The Only For-Industry, Drug Development-First, Gene Editing Summit
The toolbox of precision genome editing and delivery techniques continue to grow in 2024, enabling the community to make safer and more precise edits to a wider variety of disease targets. Translating these exciting technologies into viable therapeutic programs, however, relies on multidisciplinary technical and strategic expertise across areas in which the gene editing field is still in its infancy.
The 2024 Genome Editing Therapeutics Summit will enable you to develop, translate, and deliver novel gene editing technologies in the therapeutic setting, providing the latest data from exciting preclinical and clinical programs, and strategies on the following key topic areas:
Enable Precise Small and Large DNA Fragment Insertion : Comprehensively cover the latest platform development and drug development challenges associated with recombinase- and transposon- based editing technologies
Improve the Robustness of Your Nonclinical and Clinical Safety Packages: Navigate safety and toxicity risks, advance your on- and off- target detection strategy, and ensure clinical safety monitoring
Unlock Efficient, Cell- and Tissue- Specific Delivery: Progress lipid nanoparticles for extrahepatic delivery, overcome translational challenges of novel delivery vehicles, and tackle scale-up challenges
Leverage Regulatory Insights to Progress to the Clinic: Learn how to facilitate a successful IND submission, understand important FDA requirements ahead of commencing first-in-human trials, and unpick new draft guidance on platform technology designations
Ensure Freedom-to-Operate and Structure Profitable Licensing Deals: Develop a secure IP and patent strategy for editing and delivery technologies, establish FTO as a start-up biotech, and outline reasonable licensing deal structures
Learn from expert industry leaders, engage in meaningful group discussion, and form business connections with decision makers to accelerate your safe, precise, and regulatory-compliant programs into the clinic.
“The discussions and speakers were excellent” - Past Attendee, Johns Hopkins University
Event In Numbers
120+
Attendees
70+
Attending Groups
35+
Expert Speakers
15
New Speaking Companies
12
Novel Editing and Delivery Technology Presentations
100%
Alignment with your drug development challenges
“It covered various useful topics, from new trends in the gene editing field to clinical outcomes of CRISPR application, all of which is hard to find in one conference.” - Past Attendee, CCRM
Who Will You Meet?
The 5th Genome Editing Therapeutics Summit is dedicated to shaping the future of the genome editing field by fostering collaboration. We attract an audience of industry experts to ignite thought-provoking discussions that lead to long-term, mutually beneficial relationships in a rapidly evolving field.
This is the only industry-led, drug development-first forum dedicated to covering the safety, precision, and strategic challenges facing the field.
Uniting 120+ leaders across R&D, Delivery, Preclinical, Translational, Clinical, and Business Development domains, this year’s summit will combine both strategic and technical content to provide actional insights for groups at different stages of the value chain, from R&D through to Clinical Development.
“Great speakers, a variety of highly relevant subjects, and a nice mix of academic and biopharma attendees”
Past Attendee, Editas Medicine
